Overview

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer